About GVB Biopharma
GVB Biopharma operates two state-of-the-art hemp extraction and white labeling facilities in Central Oregon and Las Vegas, Nevada. It was founded in 2016.On May 13th, 2022, GVB Biopharma was acquired by 22nd Century Group. Terms of the transaction were not disclosed.
Missing: GVB Biopharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: GVB Biopharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing GVB Biopharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
GVB Biopharma is included in 2 Expert Collections, including Cannabis.
These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.
Agriculture Technology (Agtech)
Companies that are using technology to make farms more efficient.
Latest GVB Biopharma News
Nov 21, 2022
Established backup plans implemented to ensure continuous customer delivery Buffalo, New York--(Newsfile Corp. - November 21, 2022) - GVB Biopharma , a 22nd Century Group company (NASDAQ: XXII), today announced that a fire occurred at its GVB Biopharma distillate and isolate manufacturing facility located in Grass Valley, Oregon, on November 20, 2022. There were no reported life threatening injuries, but the fire damaged the facility. "We want to thank the first responders who were able to quickly contain the fire and prioritize the safety of local residents during this event," said James A. Mish, chief executive officer of 22nd Century Group. "Our first priority is the care of our employees who reported injuries and are receiving medical care." All Grass Valley manufacturing operations will be curtailed; however the Company is implementing backup production plans and believes its customers will experience no disruption in service or quality of products. 22nd Century is currently evaluating the extent of the damage resulting from the fire and the amount of loss is unknown at this time. The Company expects that losses resulting from the fire will be covered by its property and business interruption insurance policies. Said Mish, "While the fire at our Grass Valley facility caused serious damage, we have backup plans in place to immediately ensure our customers receive product deliveries uninterrupted. We are also implementing our contingency plan, which includes at least five separate opportunities to rapidly continue the production of our distillate and isolate products. We will carefully evaluate these options for both immediate and longer term needs so as to mitigate any potential disruption from these events. Our team is moving rapidly to assess the extent of the damage, which we expect will be covered under our property and business interruption insurance policies." About GVB Biopharma GVB Biopharma , a 22nd Century company, is a global-scale specialty ingredient supplier and contract development & manufacturing organization (CDMO) with manufacturing locations in Nevada and Oregon. GVB is the largest merchant provider of cannabinoid extracts and isolates in North America with a focus on cannabidiol (CBD) and cannabigerol (CBG) extracted and refined at an industrial scale into distillates and isolates. GVB Biopharma's facilities are NSF International audited and are cGMP Registered for dietary supplements manufacturing. GVB is widely regarded as a best-in-class operator with a leading position in the hemp-derived active ingredients market, with around 15% market share and growing. GVB is also a white-label contract manufacturer of tinctures, gel capsules, gummies, mints, tablets, topical, and vape offerings. About 22nd Century Group, Inc. 22nd Century Group, Inc. (NASDAQ: XXII) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA's Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits. Learn more about VLN® at tryvln.com . ### Cautionary Note Regarding Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 1, 2022, and in the Company's Quarterly Report filed on August 9, 2022. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law. Investor Relations & Media Contact
GVB Biopharma Web Traffic
GVB Biopharma Rank
GVB Biopharma Frequently Asked Questions (FAQ)
When was GVB Biopharma founded?
GVB Biopharma was founded in 2016.
Where is GVB Biopharma's headquarters?
GVB Biopharma's headquarters is located at 4456 E. Craig Rd., Las Vegas.
What is GVB Biopharma's latest funding round?
GVB Biopharma's latest funding round is Acquired.
How much did GVB Biopharma raise?
GVB Biopharma raised a total of $13.56M.
Who are the investors of GVB Biopharma?
Investors of GVB Biopharma include 22nd Century Group.
Who are GVB Biopharma's competitors?
Competitors of GVB Biopharma include TTS Pharma.
Compare GVB Biopharma to Competitors
Mile High Labs is an industrial-scale CBD ingredient manufacturer offering delivery of bulk CBD and co-packing services to consumer brands. With an end-to-end GMP certified extraction facility and extensive network of contracted cultivators, Mile High Labs supplies high-quality, high-volume CBD orders year round. Mile High Labs extracts exclusively from industrial hemp flower material.
PharmaHemp is a global company specialized in hemp solutions. It is a grower of organic hemp and a producer and supplier of cannabidiol (CBD).
Folium Biosciences is an integrated producer, manufacturer, and distributor of hemp-derived phytocannabinoids in the United States. Folium Biosciences also owns and operates a phytocannabinoid extraction and purification facility.
TTS Pharma is a UK-based, vertically integrated company producing high quality, safe Cannabinoid products for the ethical cannabis market, working within existing legislation and meeting all the legal requirements of the UK's Home Office, the Food Standards Agency and Trading Standards, and all legal requirements in Europe.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.